Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is highly correlated with early stage lung cancer.
Company Details
- Employees
- 4
- Address
- 60 Gracechurch Street, 6th Floor,united Kingdom
- Industry
- Medical Device
- Website
- https://cizzlebiotechnology.com
- HQ
- London
Cizzle Biotechnology Plc Questions
Cizzle Biotechnology Plc's website is https://cizzlebiotechnology.com
Cizzle Biotechnology Plc's LinkedIn profile is https://uk.linkedin.com/company/cizzle-biotechnology-plc
Cizzle Biotechnology Plc has
4 employees.
View email and phone details for 4
employees at Cizzle Biotechnology Plc.
Cizzle Biotechnology Plc's industry is
Medical Device
Cizzle Biotechnology Plc's top competitors are
Industrial Biotechnology Innovation Catalyst,
Rq Biotechnology Ltd.,
Ab Biotechnology Limited,
King’s Biotechnology And Synthetic Biology Society,
Genz Biotechnology,
Pebble Biotechnology Laboratories,
Cizzle Bio, Inc.,
Enbiosis Biotechnology,
Eon Biotechnology,
Arcis Biotechnology.
Cizzle Biotechnology Plc's categories are Medical Device
